FDA approves Sarclisa for relapsed refractory multiple myeloma
The approval of the monoclonal antibody “provides a new treatment option for patients whose disease has returned or become resistant to their prior treatments.”
Read More
Author: Anna Smith
Xpovio hits endpoints in Phase III multiple myeloma trial
The drug achieved a median progression-free survival of 13.93 months, compared to 9.46 months on Velcade (bortezomib).
Read More
Keytruda improves PFS in classical Hodgkin lymphoma
The drug went head-to-head with brentuximab vedotin (BV) – also sold as Adcetris by Seattle Genetics.
Read More
Gilead strikes $4.9bn deal to buy Forty Seven
The acquisition is set to strengthen Gilead’s immuno-oncology research and development portfolio with drugs such as Forty Seven’s magrolimab.
Read More
GW Pharma regains Sativex rights in UK
The company is taking the reins back from Bayer.
Read More- Subcutaneous pembrolizumab begins rollout across NHS hospitals
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
